tiprankstipranks
Rapid Therapeutic Science Laboratories (RTSL)
OTHER OTC:RTSL
US Market
RTSL
Rapid Therapeutic Science Laboratories
RESEARCH TOOLSreports

Rapid Therapeutic Science Laboratories (RTSL) Income Statement

28 Followers

Rapid Therapeutic Science Laboratories Income Statement

Last quarter (Q2 2023), Rapid Therapeutic Science Laboratories's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Rapid Therapeutic Science Laboratories's net income was $46.42K. See Rapid Therapeutic Science Laboratories’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 19Dec 17
Total Revenue
$ 0.00$ 534.00$ 9.14K$ 0.00
Gross Profit
$ 0.00$ 334.00$ 1.98K$ 0.00
Operating Expenses
$ 1.26M$ 2.17M$ 169.69K$ 152.07K
Depreciation and Amortization
$ 23.97K$ 55.86K$ 1.38K$ 16.39K
EBITDA
$ -1.24M$ -2.11M$ -168.31K$ -135.68K
Operating Income
$ -1.26M$ -2.17M$ -169.69K$ -2.52M
Other Income/Expenses
$ -531.39K$ -697.59K$ 1.38K$ -2.37M
Pretax Income
$ -1.79M$ -2.87M$ -348.84K$ -2.55M
Net Income
$ -1.69M$ -4.20M$ -348.84K$ -2.55M
Per Share Metrics
Basic EPS
$ -0.22$ -0.55$ -7.24$ -25.88
Diluted EPS
$ -0.22$ -0.55$ -7.24$ -25.88
Weighted Average Shares Outstanding
 7.75M 7.63M 48.16K 98.64K
Weighted Average Shares Outstanding (Diluted)
 7.75M 7.63M 48.16K 98.64K
Currency in USD

Rapid Therapeutic Science Laboratories Earnings and Revenue History